Acanthosis nigricans
Lisa Rappoport, Dirk Schadendorf(National Center for Tumor Diseases), Julia Vaübel(University of Duisburg-Essen), Joachim Dissemond(Essen University Hospital), Elvir Cesko(Essen University Hospital), Nadine Voshege, Thomas Jansen(Ruhr University Bochum), Sarah Piel(Düsseldorf University Hospital), Andreas Körber(Ruhrlandklinik)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k